CACNA2D2
Voltage-dependent calcium channel subunit alpha-2/delta-2
As of the edition of 20 October 2026, CACNA2D2 (voltage-dependent calcium channel subunit alpha-2/delta-2, UniProt Q9NY47) has 2 drugs tested at it and 2 companies on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9NY47
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Disease areas
- Nervous system; Bones, joints and muscles; Hormones; Nutrition and metabolism; Pregnancy and women's health; Urinary and reproductive
- Registered trials of its drugs
- 20
Drugs at this target
| Status | Count |
|---|---|
| Active | 1 |
| Status not established | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Mirogabalin | Active | Phase 4 | none listed |
| YHD1119 | Status not established | Phase 1 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Engaged | 1 |
| Undetermined | 1 |
| Total on the list | 2 |